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Pregnancy outcomes in women with
gestational diabetes mellitus diagnosed
according to the WHO-2013 and WHO-
1999 diagnostic criteria: a multicentre
retrospective cohort study
Eva A. R. Goedegebure1†, Sarah H. Koning2*†, Klaas Hoogenberg3, Fleurisca J. Korteweg4, Helen L. Lutgers5,
Mattheus J. M. Diekman6, Eva Stekkinger1, Paul P. van den Berg7 and Joost J. Zwart1
Abstract
Background: The World Health Organization (WHO) adopted more stringent diagnostic criteria for GDM in 2013, to
improve pregnancy outcomes. However, there is no global consensus on these new diagnostic criteria, because of
limited evidence. The objective of the study was to evaluate maternal characteristics and pregnancy outcomes in
two cohorts in the Netherlands applying different diagnostic criteria for GDM i.e. WHO-2013 and WHO-1999.
Methods: A multicenter retrospective study involving singleton GDM pregnancies in two regions, between 2011
and 2016. Women were diagnosed according to the WHO-2013 criteria in the Deventer region (WHO-2013-cohort)
and according to the WHO-1999 criteria in the Groningen region (WHO-1999-cohort). After GDM diagnosis, all
women were treated equally based on the national guideline. Maternal characteristics and pregnancy outcomes
were compared between the two groups.
Results: In total 1386 women with GDM were included in the study. Women in the WHO-2013-cohort were older
and had a higher pre-gestational body mass index. They were diagnosed earlier (24.9 [IQR 23.3–29.0] versus 27.7
[IQR 25.9–30.7] weeks, p = < 0.001) and less women were treated with additional insulin therapy (15.6% versus 43.
4%, p = < 0.001). Rate of spontaneous delivery was higher in the WHO-2013-cohort (73.1% versus 67.4%, p = 0.032).
The percentage large-for-gestational-age (LGA) neonates (birth weight > 90th percentile, corrected for sex, ethnicity,
parity, and gestational age) was lower in the WHO-2013- cohort, but not statistical significant (16.5% versus 18.5%,
p = 0.379). There were no differences between the cohorts regarding stillbirth, birth trauma, low Apgar score, and
preeclampsia.
Conclusions: Using the new WHO-2013 criteria resulted in an earlier GDM diagnosis, less women needed insulin
treatment and more spontaneous deliveries occurred when compared to the cohort diagnosed with WHO-1999
criteria. No differences were found in adverse pregnancy outcomes.
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Background
Gestational diabetes mellitus (GDM) is defined as glucose
intolerance detected during pregnancy [1]. The prevalence
of GDM is increasing and affects between 1 and 14% of all
pregnancies, caused by a global increase in the number of
women with obesity around reproductive age and by more
stringent diagnostic criteria for GDM [1–4]. Untreated
GDM is associated with an increased rate of neonatal and
obstetric complications [5–7]. Adverse pregnancy out-
comes have been shown to improve with timely diagnosis
and treatment of GDM [8].
In 2008, the international prospective Hyperglycemia
and Adverse Pregnancy Outcomes (HAPO) study group
demonstrated a continuous association between maternal
hyperglycaemia and risk of adverse pregnancy outcomes,
as birth weight greater than the 90th percentile, caesarean
section, premature birth, birth injury, and preeclampsia
[9]. Based on these findings and earlier observational stud-
ies, the International Association of Diabetes and Preg-
nancy Study Group (IADPSG) proposed more stringent
diagnostic thresholds for GDM [10]. These new diagnostic
criteria (fasting plasma glucose level ≥ 5.1 mmol/l and/or
1-h plasma glucose level ≥ 10.0 mmol/l and/or 2-h plasma
glucose level ≥ 8.5 mmol/l) have been adopted by the
American Diabetes Association in 2010, the World Health
Organization (WHO) in 2013, and the International Fed-
eration of Gynaecology and Obstetrics in 2015 [1, 11, 12].
However, to date there is no global consensus on these
new diagnostic criteria. A recent review on the current
European situation showed a lack of consistency on
GDM diagnosis [13]. The apparent reluctance to adopt
the IADPSG criteria may result from studies showing an
increase in prevalence of GDM and thus a higher burden
to obstetric healthcare providers [4, 14], but most im-
portantly from scepticism about the clinical benefit of
lower diagnostic thresholds [14, 15].
Also in the Netherlands there is a debate regarding the
diagnostic criteria for GDM. The Dutch Society of Ob-
stetrics and Gynaecology guideline 2010 “Diabetes and
Pregnancy” recommends screening for GDM in high-
risk women using the 2-h 75-g oral glucose tolerance
test (OGTT) using the older WHO-1999 criteria, utiliz-
ing a fasting blood glucose ≥7.0 and 2-h blood glucose
of ≥7.8 mmol/l [16, 17]. Notwithstanding that, a few
hospitals in the Netherlands already implemented the
new WHO-2013 thresholds for diagnosis of GDM.
To verify the consequences of implementing these
new WHO-2013 thresholds the following question need
to be answered: What are the pregnancy outcomes of
women diagnosed according the WHO-2013 criteria
compared with women diagnosed according the older
WHO-1999 criteria?
The objective of the current study was therefore to
evaluate the maternal characteristics and obstetric and
neonatal outcome in two typical population-based co-
horts in the Netherlands which applied the two differ-




A multicentre, retrospective cohort study was conducted
involving three hospitals in the Netherlands (University
Medical Center Groningen a tertiary care centre, Martini
Hospital Groningen, and Deventer Hospital both sec-
ondary care centres). Both regions (Deventer region and
Groningen region) are located in the relatively rural
north-eastern part of the Netherlands. Part of the data
of the Groningen region has been published previously
[18, 19]. All pregnant women with diagnosis of GDM
were eligible for inclusion in the study. Women with a
twin pregnancy and women with pre-existing diabetes
mellitus (DM) were excluded.
This study has been conducted in accordance with the
guidelines of the Declaration of Helsinki and Good Clinical
Practice. The patient data were retrospectively acquired
from hospital records generated during care-as-usual. Stat-
istical analysis was performed requiring patient anonymity
in agreement with the ethics committee regulations [20].
According to the Dutch law on Medical Research with Hu-
man Subjects, this study has been exempted for approval
by the local ethics committees.
Screening, diagnosis and treatment of GDM
Criteria for screening and diagnosis of GDM are sum-
marized in Fig. 1 [16, 17]. After GDM diagnosis all
women were treated based on the national guideline.
First, all women received dietary counselling and in-
structions for self-monitoring of the blood glucose levels
(SMBG). According to the guideline, insulin therapy was
started if the blood glucose levels were repeatedly above
the treatment targets (two blood glucose values above
the treatment target at the same day) despite dietary
treatment: fasting blood glucose level > 5.3 mmol/l and/
or either a 1-h postprandial blood glucose level > 7.
8 mmol/l, or 2-h postprandial blood glucose level > 6.
7 mmol/l. Options for insulin therapy regimens were:
ultra-short-acting insulin, once daily long-acting insulin,
or a combination of both (basal-bolus). Metformin was
occasionally prescribed in obese women (body mass
index (BMI) > 30 kg/m2) in the Deventer hospital
(depending on glycaemic control). Based on SMBG
women were advised to adjust diet or increase insulin-
or metformin dose to maintain blood glucose levels
within the target range.
Women were seen at the obstetric outpatient clinic
regularly and foetal growth was evaluated by ultrasonog-
raphy at least every 4 weeks. Moreover, all patients were
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discussed every two to three weeks multidisciplinary.
Based on similar guidelines in the two regions labour was
induced between 38 and 39 weeks of gestation in women
on insulin therapy or earlier on indication. In women with
a diet, labour was induced between 38 and 40 weeks tak-
ing glycaemic control, estimated foetal weight and non-
GDM related risk factors into consideration.
Outcomes and definitions
All electronic medical- and birth records were retro-
spectively reviewed and data between 2011 and 2016
were included in an anonymised database. Maternal
characteristics were age, ethnicity (Caucasian, Asian,
African American, Mediterranean or unknown), parity,
pre-gestational BMI, risk factors for GDM, hypertensive
disorders, results of 75-g OGTT, and treatment details.
Chronic hypertension was defined as a systolic blood
pressure (SBP) ≥140 mmHg and/or a diastolic blood
pressure (DBP) ≥90 mmHg at booking before 20 weeks
of gestation, or the use of blood-pressure lowering drugs
before pregnancy.
Obstetric and neonatal outcomes
Obstetric outcomes collected were induction of labour,
mode of delivery (spontaneous vaginal delivery, assisted
vaginal delivery (vacuum extraction or forceps), intrapar-
tum caesarean delivery or planned caesarean delivery),
gestational age at birth, pregnancy-induced hypertension
(PIH) and preeclampsia. PIH was defined as a SBP
≥140 mmHg and/or a DBP ≥90 mmHg, after 20 weeks
of gestation in a previously normotensive woman. Pre-
eclampsia was defined ad PIH plus the presence of pro-
teinuria (≥300 mg/24-h) and also included women who
had eclampsia and HELLP syndrome.
Neonatal outcomes were birth weight, large for gesta-
tional age (LGA; birth weight > 90th percentile, cor-
rected for sex, ethnicity, parity, and gestational age) [21],
small for gestational age (SGA; birth weight < 10th
percentile, corrected for sex, ethnicity, parity, and gesta-
tional age) [21], preterm delivery (delivery before
37 weeks of gestation), 5 min Apgar score < 7, need for
respiratory support, still birth/neonatal death, birth
trauma (shoulder dystocia, fracture of humerus or clav-
icle, brachial plexus injury), neonatal hypoglycaemia,
Fig. 1 Screening and diagnosis of gestational diabetes. Abbreviations: GDM, gestational diabetes mellitus; WHO, World Health Organization;
OGTT, oral glucose tolerance test; BMI, body mass index; DM; diabetes mellitus; IUFD, intra uterine foetal death; PCOS, polycystic ovary syndrome
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neonatal hyperbilirubinaemia, and admission to the neo-
natology department. Of note, neonates with extreme
prematurity (delivery before 28 weeks of gestation, n =
3) were excluded prior to the analysis for the variable
birth weight. Hyperbilirubinaemia was recorded if the
neonate required treatment with phototherapy after
birth. Neonatal hypoglycaemia (occurring > 2-h after
birth) was defined as a blood glucose level < 2.6 mmol/l
or treatment with glucose infusion [16]. Neonates born
before 32 weeks (n = 2) of gestation with neonatal
hypoglycaemia were excluded prior to the analysis as
hypoglycaemia could well be caused by prematurity. Re-
spiratory support was defined as the need for continuous
positive airway pressure after birth or intubation.
Statistical analyses
Statistical analyses were carried out using statistical
package IBM SPSS (version 23.0. Armonk, NY: IBM
Corp). Continuous variables are presented as mean ±
standard deviation (SD) or as median and inter quartile
range (IQR) according to the normal distribution status.
Categorical variables are presented as numbers and fre-
quencies (%). Appropriate (non)parametric tests were
used to compare differences between the groups for con-
tinuous variables (independent t-test or Mann-Whitney
U-test in case of skewed distribution) and categorical
variables (Chi-square or Fisher’s exact test).
To examine the associations between the diagnostic
groups and pregnancy outcomes, analyses were per-
formed using logistic regression models in which the
ORs and 95% CIs for the WHO-2013 group were calcu-
lated using the WHO-1999 group as reference group.
Results were presented as unadjusted models and
multivariable-adjusted models, with the multivariable-
adjusted models adjusted for maternal age, pre-
pregnancy BMI, ethnicity and parity. Only for the vari-
ables with sufficient statistical power multivariable-
adjusted models were performed. The model analysing
the association between the diagnostic groups and LGA-
neonates was adjusted for maternal age and pre-
pregnancy BMI. P-value < 0.05 was considered statisti-
cally significant.
Results
Maternal characteristics are summarized in Table 1. A
total of 1386 women with GDM were included in the
study, 437 in the WHO-2013-cohort and 949 in the
WHO-1999-cohort. In the WHO-2013-cohort, 49.4% of
the women had GDM according to both the WHO-1999
criteria and WHO-2013 criteria. In the WHO-1999-
cohort, 24.7% of the GDM women would not have had
GDM according to the WHO-2013 criteria.
In total, 1341 women (96.4%) were diagnosed by
OGTT and 45 (3.6%) women were already diagnosed in
first trimester by a random or fasting glucose level. The
median fasting glucose level was higher in the WHO-
2013-cohort and the 2-h glucose level was lower, com-
pared to the WHO-1999-cohort. GDM diagnosis was
based on elevated fasting glucose level only in 40.2% in
the WHO-2013-cohort, compared with 0.8% in the
WHO-1999-cohort. GDM was diagnosed based on ele-
vated 2-h value in 10.9% in the WHO-2013-cohort and
in 95.4% in the WHO-1999-cohort. Women in the
WHO-2013-cohort were diagnosed earlier in pregnancy
(24.9 [IQR 23.3–29.0] vs. 27.7 [IQR 25.9–30.7] weeks)
and less women had their OGTT performed based on
symptoms or signs in third trimester (15.1% vs. 28.5%)
instead of screening based on predefined GDM risk-
factors. Of the 270 women in the WHO-1999-cohort di-
agnosed with GDM based on signs suggestive of GDM,
127 (47.0%) retrospectively appeared to have risk factors
for GDM. Of these, 12 women tested negative on a first
OGTT in the 2nd trimester and 115 women were not
screened. In the WHO-2013-cohort 15.6% of the women
received insulin treatment compared with 43.4% in the
WHO-1999-cohort. In the WHO-2013-cohort, 14 (3.2%)
women were treated with metformin.
Obstetric and neonatal outcome
Table 2 summarizes the obstetric outcomes. In the
WHO-2013-cohort there were more spontaneous deliv-
eries (73.1% vs. 67.4%, adjusted OR 1.52 (1.15–2.01)),
less planned caesarean deliveries (7.8% vs. 11.7%, OR 0.
64 (0.43–0.96)). Median gestational age at birth was
higher for women in the WHO-2013-cohort (39.0 vs. 38.
3 weeks, p = < 0.001) and women in the WHO-2013-
cohort were less like to have induced labour (59.3% vs.
63.9%, adjusted OR 0.76 (0.59–0.98). There were no dif-
ferences between the groups with respect to assisted va-
ginal delivery and intrapartum caesarean delivery.
Prevalence of PIH was higher in the WHO-2013-cohort,
although no differences were seen between the two
groups regarding incidence of preeclampsia.
Table 3 shows the neonatal outcomes. The percentage
of LGA neonates (corrected for sex, ethnicity, parity,
and gestational age) was lower in the WHO-2013-cohort
(16.5% vs. 18.5%, adjusted OR 0.90 (0.66–1.25)), but this
was not statistical significant. Birth weight was accord-
ingly higher (3512 vs. 3399 g, p = < 0.001). Neonatal
hypoglycaemia was more often diagnosed in offspring of
the WHO-2013-cohort (9.6% vs. 4.2%, adjusted OR 2.48
(1.52–4.05)). There were no significant differences seen
between the two groups with respect to neonatal hyper-
bilirubinaemia, preterm delivery, birth weight in categor-
ies, SGA, 5 min Apgar score < 7, need for respiratory
support, birth trauma, still birth/neonatal death, and ad-
mission to the neonatology department.
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Table 1 Maternal characteristics of women diagnosed with gestational diabetes mellitus
Cohort
Characteristics WHO-2013 WHO-1999 P-value*
N 437 949
Age (years) 34.7 ± 5.1 32.1 ± 5.1 < 0.001
Ethnicity, n (%) < 0.001
Caucasian 357 (81.7) 741 (78.1)
Asian 9 (2.1) 72 (7.6)
African-American 2 (0.5) 39 (4.1)
Mediterranean 64 (14.6) 69 (7.3)
Unknown 5 (1.1) 28 (3.0)
Parity, n (%) 0.232
0 158 (36.2) 386 (40.7)
1–2 242 (55.5) 499 (52.6)
> 2 36 (8.3) 64 (6.7)
First degree relative with DM, n (%) 82 (18.8) 376 (41.1) < 0.001
History of PCOS, n (%) 10 (2.3) 50 (5.3) 0.011
History of GDM, n (%) 44 (10.1) 103 (10.9) 0.650
Previous infant weighing ≥4500 g at birth, n (%) 42 (9.6) 97 (10.2) 0.716
History of IUFD, n (%) 4 (0.9) 20 (2.1) 0.113
Pre-gestational BMI (kg/m2) 29.7 [26.0–34.4] 27.7 [24.2–31.8] < 0.001
Pre-gestational BMI, n (%) < 0.001
< 25 kg/m2 88 (20.8) 291 (31.5)
25–29.9 kg/m2 129 (30.4) 288 (31.2)
≥ 30 kg/m2 207 (48.8) 344 (37.3)
Chronic hypertension, n (%) 8 (1.8) 43 (4.5) 0.013
Indication for OGTT, n (%) < 0.001
Screening based on risk factors 362 (82.8) 650 (68.5)
Diagnostic test based on symptoms/signs 66 (15.1) 270 (28.5)
Unknown 9 (2.1) 29 (3.1)
Diagnosis based on OGTT, n (%)‡ 422 (96.6) 919 (96.8) 0.791
Gestational age at time of OGTT (weeks) 24.9 [23.3–29.0] 27.7 [25.9–30.7] < 0.001
Gestational age at time of OGTT screening only (weeks) 24.4 [22.6–26.9] 27.3 [25.1–28.7] < 0.001
Gestational age at time of OGTT diagnostic 3rd trimester only (weeks) 33.1 [28.7–35.3] 30.4 [27.7–33.6] 0.001
75-g OGTT
Fasting glucose level (mmol/l) 5.3 [5.1–5.6] 5.0 [4.6–5.5] < 0.001
1-h glucose level (mmol/l) 9.6 [8.0–10.5] – NA
2-h glucose level (mmol/l) 7.7 [6.6–9.0] 8.6 [8.1–9.4] < 0.001
Diagnosis based on elevated fasting glucose level only, n (%) 170 (40.2) 8 (0.9) < 0.001
Diagnosis based on elevated 2-h glucose level only, n (%) 46 (10.9) 877 (95.4) < 0.001
Insulin treatment, n (%) 68 (15.6) 412 (43.4) < 0.001
Metformin treatment, n (%) 14 (3.2) – NA
Abbreviations: WHO World health Organization, BMI body mass index, DM diabetes mellitus, IUFD intrauterine foetal death, PCOS polycystic ovary syndrome, OGTT
oral glucose tolerance test, NA not applicable. Data are expressed as mean ± SD, median [IQR], or proportion of n (%)
*P-values were based on Student’s unpaired t-test (non-skewed continuous variables), Mann-Whitney U-Test (skewed continuous variables) or chi-square test
(categorical variables)
‡Total number of women diagnosed with a 75-g OGTT. The other women (n = 45) were diagnosed with a random or fasting glucose level in first trimester of their
pregnancy. Data with respect to first degree relative with DM 35 (3.7%) (WHO-1999-cohort), BMI 13 (3.0%) (WHO-2013-cohort) and 26 (2.7%) (WHO-1999-cohort),
gestational age at time of OGTT 15 (1.6%) (WHO-1999-cohort), are missing
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Discussion
This multicentre, retrospective cohort study shows the
pregnancy outcomes in two cohorts applying different
diagnostic criteria for GDM i.e. WHO-2013 and WHO-
1999. Women in the WHO-2013-cohort had a higher
pre-gestational BMI and more often PIH. However, they
were diagnosed earlier, less often needed insulin therapy
and had a higher percentage of spontaneous deliveries.
No other differences in adverse obstetric and neonatal
outcomes were seen between the two cohorts.
A number of previous international studies have ad-
dressed the effects of introduction of the WHO-2013
Table 2 Obstetric outcomes of women diagnosed with gestational diabetes mellitus
Cohort
Outcome variable WHO-2013 WHO-1999 P-value* OR** Adjusted OR**
N 437 949
Induction of labour, n (%) 256 (59.3) 606 (63.9) 0.102 0.82 (0.65–1.04) 0.76 (0.59–0.98)
Delivery type, n (%)
Spontaneous vaginal delivery 318 (73.1) 638 (67.4) 0.032 1.32 (1.02–1.70) 1.52 (1.15–2.01)
Assisted vaginal delivery 35 (8.0) 79 (8.3) 0.712 0.93 (0.61–1.40) NA
Intrapartum caesarean delivery 48 (11.0) 121 (12.8) 0.365 0.85 (0.60–1.21) NA
Planned caesarean delivery 34 (7.8) 111 (11.7) 0.029 0.64 (0.43–0.96) NA
Gestational age at birth (weeks) 39.0 [38.3–39.6] 38.3 [38.0–39.0] < 0.001 NA NA
Pregnancy-induced hypertension, n (%) 50 (11.5) 61 (6.4) 0.001 1.89 (1.28–2.80) 1.71 (1.11–2.63)
Preeclampsia, n (%) 12 (2.8) 30 (3.2) 0.683 0.87 (0.44–1.71) NA
Abbreviations: WHO World health Organization, OR odds ratios, NA not applicable. Data are expressed as mean ± SD, or proportion of n (%)
*P-values were based on Student’s unpaired t-test (non-skewed continuous variables), or chi-square test (categorical variables)
**OR, 95% confidence intervals were derived from logistic regression models using the WHO-1999 group as reference group. Multivariable adjustment included
maternal age, pre-gestational body mass index, ethnicity and parity. When the statistical power of a variable was not sufficient or the outcome variable was
continuous ‘NA’ was reported
Table 3 Neonatal outcomes of women diagnosed with gestational diabetes mellitus
Cohort
Outcome variable WHO-2013 WHO-1999 P-value* OR** Adjusted OR**
N 437 949
Preterm delivery, n (%) 27 (6.2) 60 (6.3) 0.934 0.98 (0.61–1.57) NA
Birth weight (g) 3512 ± 459 3399 ± 532 < 0.001 NA NA
Birth weight, n (%) 0.136 NA NA
Infants < 4000 g 384 (87.9) 831 (87.8)
Infants 4000–4499 g 42 (9.6) 104 (11.0)
Infants ≥4500 g 11 (2.5) 11 (1.2)
Large for gestational age, n (%) ‡ 72 (16.5) 176 (18.5) 0.379 0.87 (0.65–1.18) 0.90 (0.66–1.25)
Small for gestational age, n (%) ‡ 14 (3.2) 37 (3.9) 0.538 0.82 (0.44–1.54) NA
5 min Apgar < 7, n (%) 7 (1.6) 32 (3.4) 0.068 0.47 (0.21–1.08) NA
Respiratory support, n (%) 14 (3.2) 37 (3.9) 0.519 0.81 (0.44–1.52) NA
Birth trauma, n (%) 15 (3.4) 30 (3.2) 0.791 1.09 (0.58–2.05) NA
Hypoglycaemia, n (%) 42 (9.6) 40 (4.2) < 0.001 2.41 (1.54–3.78) 2.48 (1.52–4.05)
Hyperbilirubinaemia, n (%) 4 (0.9) 24 (2.5) 0.062 0.36 (0.12–1.03) NA
Still birth/neonatal death, n (%) 1 (0.2) 2 (0.2) 1.000 NA NA
Admission to the neonatology department, n (%) 54 (12.4) 139 (14.6) 0.272 0.83 (0.59–1.16) 0.79 (0.55–1.14)
Abbreviations: WHO World health Organization, OR odds ratios, NA not applicable. Data are expressed as mean ± SD, or proportion of n (%)
*P-values were based on Student’s unpaired t-test (non-skewed continuous variables), or chi-square test (categorical variables)
**OR, 95% confidence intervals were derived from logistic regression models using the WHO-1999 group as reference group. Multivariable adjustment included
maternal age, pre-gestational body mass index, ethnicity and parity. Large for gestational age was adjusted for maternal age and pre-gestational body mass index.
Only for the variables with sufficient statistical power multivariable adjustment was performed. When the statistical power was not sufficient or the outcome
variable was continuous ‘NA’ was reported
‡Corrected for sex, ethnicity, parity, and gestational age
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criteria on pregnancy outcomes [22–27]. They retro-
spectively studied pregnancy outcomes in women previ-
ously classified as non-GDM with other diagnostic
criteria and newly defined as GDM with the WHO-2013
criteria [22–27]. These studies suggested that women
newly diagnosed with the WHO-2013 criteria if un-
treated were at increased risk for adverse pregnancy out-
comes, including PIH, preeclampsia, neonatal intensive
care admission, caesarean section, shoulder dystocia,
macrosomia and LGA neonates, compared to non-GDM
women [22–27]. In contrast to the aforementioned stud-
ies, women in our study both diagnosed with WHO-
2013 or WHO-1999 criteria were treated similarly ac-
cording to our national guideline. Two comparable stud-
ies with regard to treatment and comparison of two
diagnostic approaches (Carpenter-Coustan criteria com-
pared with the WHO-2013 criteria) showed that the per-
centage of LGA neonates was lower in the WHO-2013-
cohort [28, 29]. In addition, one study also showed a re-
duction in caesarean deliveries, PIH, and assisted deliv-
ery after implementation of the WHO-2013 criteria [29].
In terms of the likelihood of having an LGA neonate,
we found no significant differences between women di-
agnosed having GDM on the WHO-2013 criteria and
women diagnosed having GDM on the WHO-1999 cri-
teria. However, the percentage LGA neonates was lower
in the WHO-2013-cohort. The reduction of LGA neo-
nates is an important treatment target in GDM, since
LGA is associated with short- and long term complica-
tions for the neonate. There are several potential expla-
nations for the lower rates of LGA neonates in the WHO-
2013-cohort found in our study and others [28, 29].
Firstly, the WHO-2013 criteria included a new group of
women: 40.2% of the women were only diagnosed based
on the fasting glucose cut-off value compared to 0.8% in
the WHO-1999-cohort. By applying the more strict
WHO-2013 criteria the prevalence of GDM increases, in-
cluding presumably more mild cases of GDM, resulting in
a lower percentage of LGA neonates. Several other studies
have demonstrated that implementation of the WHO-
2013 increases the prevalence of GDM [4, 14]. Moreover,
a lower percentage of women in our WHO-2013-cohort
(15.6%) required additional insulin therapy compared with
the WHO-1999-cohort (43.4%).
Secondly, women in the WHO-2013-cohort were
screened and diagnosed with GDM earlier (WHO-2013-
cohort: median ~ 25 weeks, WHO-1999-cohort: median
~ 28 weeks), so that group had earlier dietary or insulin
intervention. More women in the WHO-1999-cohort
were diagnosed based on signs suggestive of GDM (e.g.
polyhydramnios/foetal macrosomia). Therefore the
WHO-1999-cohort may include women with a more
advanced stage of GDM leading to higher rates of
LGA. Nevertheless, approximately 50% of all women
diagnosed with GDM based on signs suggestive of
GDM, retrospectively had a risk factor for GDM that
justified 2nd trimester screening in the first place. However,
even when we only considered women who were diagnosed
based on 2nd trimester screening because of GDM risk fac-
tors, gestational age at diagnoses remained different be-
tween the groups. The earlier screening and diagnosis of
GDM in the WHO-2013-cohort could have led to earlier
treatment and therefore to a better outcome. Landon et al.
also demonstrated that offering early treatment to women
with modest degrees of hyperglycaemia in pregnancy re-
sults in reduction of foetal overgrowth [30].
The only obstetric parameters which differed between
the two cohorts were the higher incidence of planned
caesarean section and induction of labour in the WHO-
1999-cohort. This may be due to difference in clinical
obstetric practice between both regions. But may also be
due to differences related to GDM including more esti-
mated macrosomia on ultrasound, worse glycaemic con-
trol indicated by significantly more insulin therapy.
An increase in neonatal hypoglycaemia was seen in
the WHO-2013-cohort. This can be explained by an ac-
tive screening policy in all neonates in the hospital that
used the WHO-2013 criteria unlike the “WHO-1999 hos-
pitals”, that screened neonates by indication. This finding
suggests that roughly 50% neonatal hypoglycaemia might
be missed without active screening, potentially leading to
long-term adverse outcomes. Moreover, in the WHO-
2013-cohort a higher percentage of women were diag-
nosed with PIH. In the WHO-1999-cohort more women
were diagnosed with chronic hypertension in first trimes-
ter of their pregnancy. This finding suggests that the dif-
ference in PIH between the WHO-2013-cohort and
WHO-1999-cohort also can be explained by an earlier
diagnosis of chronic hypertension in first trimester in the
WHO-1999 cohort.
This study gives no information on differences in inci-
dence of GDM between the two diagnostic approaches.
In the WHO-2013-cohort, 50.6% of the women were
positive for GDM according the WHO-2013 criteria only
and 49.4% had GDM according to both the WHO-2013
criteria and WHO-1999 criteria. Both cohorts differed in
some clinical characteristics: women in the WHO-2013
cohort were older, had a higher pre-gestational BMI and
were more often diagnosed on the fasting glucose level
compared with the WHO-1999-cohort. These factors
are associated with a less favourable metabolic profile.
Although the WHO-2013-cohort seemingly consisted of
a group of women with milder glucose intolerance, they
appeared to have a worse metabolic profile. It seems that
the WHO-2013 criteria have a better ability to select
women with a worse metabolic profile.
The main strength of this study is that it evaluates the
pregnancy outcomes of women with GDM diagnosed by
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the old and new WHO-criteria in a real-life clinical set-
ting. Moreover, after GDM diagnosis all women were
treated equally based on the national guideline. Several
potential limitations of this study should be noted. First,
this study was conducted in three different hospitals in
two regions of the Netherlands. It is possible that the
study populations and obstetric management between
the hospitals were different. One centre is a tertiary care
centre and two are larger secondary care centres and
this might have led to a selection bias. However, the only
important difference between secondary care centres
and tertiary care centres in the Netherlands is the refer-
ral function for deliveries under 32 weeks of gestational
age for neonatal purposes. In all other aspects, popula-
tion and care is comparable. Secondly, the study was
limited by its retrospective study design and this resulted
in missing data for some variables in the electronic med-
ical- and birth records. Thirdly, the sample size was lim-
ited to find significant differences between the groups
for relatively rare pregnancy outcomes, such as birth
trauma, still birth/neonatal death, and preeclampsia.
Due to the lack of statistical power for some pregnancy
outcomes it was not possible to adjust these outcomes
for possible confounding factors. Finally, this study gives
no information on differences in incidence of GDM be-
tween the two diagnostic approaches since the exact
number of pregnant women in the two populations is
not known. The national guideline advocate targeted
testing for GDM, and therefore we do not have data on
universal testing.
Conclusions
In summary, this study demonstrated that application of
the WHO-2013 criteria was associated with a reduced
need for insulin treatment and more spontaneous deliv-
eries. Although an earlier diagnosis of GDM might con-
tribute to these differences, milder GDM by selection is
proposed to play a major role. No differences were
found in adverse pregnancy outcomes between the two
diagnostic approaches.
This study contributes to the current debate regarding
the value of implementation of new WHO-2013 diag-
nostic criteria for GDM but cannot provide a definitive
answer. The data of well conducted population-based
randomised studies (and meta-analyses) directly compar-
ing the two diagnostic approaches are necessary to de-
termine whether treatment of women with mild GDM is
beneficial and cost-effective. Moreover, there is more in-
formation needed whether women with a 2-h glucose
value between ≥7.8 - ≤8.4 mmol/l can be safely left
untreated.
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